Eli Lilly and Co. passed up the chance to develop a vaccine and instead focused on making antibody treatments for patients who were already infected with the coronavirus. That turned out to be a financial whiff. Now all eyes will be on Lilly’s second-quarter earnings, which the company will release early Tuesday.
Even as some drugmakers, including Indianapolis-based Eli Lilly and Co., are pushing to get experimental drugs approved, federal regulators are still dealing with a huge blowback over the controversial way they reviewed a new Alzheimer’s drug by rival Biogen.
The Indianapolis-based drugmaker said the deal to buy Protomer Technologies could be worth up to $1 billion if the technology meets certain milestones. Lilly did not say how much it was paying up front in cash.
The collaboration could be worth as much as $694 million and potential royalties to Verge Genomics if the two companies hit development milestones.
The role of the sticky substance in the brain has long divided researchers and is at the forefront again amid the FDA’s recent clearance of the first drug to treat the disease in almost two decades.
In her complaint, the lobbyist had claimed a top executive made sexist comments about her, mocked her physical appearance and subjected her and other women to a hostile work environment.
Eli Lilly and Co. shares jumped more than 9% Thursday morning after it received “breakthrough therapy” designation for donanemab from the U.S. Food and Drug Administration, putting the drug on a path that could expedite its development.
Mathilde Merlet oversees one of Eli Lilly and Co.’s fastest-growing products, a medicine called Taltz that treats a variety of dermatology and rheumatology disorders.
The use of COVID antibodies has fallen across the United States lately and, along with it, Lilly’s sales in that category.
Shares of Biogen competitors soared after aducanumab became the first drug cleared by the U.S. Food and Drug Administration to slow the course of the mind-wasting disease that afflicts 6 million Americans.
For more than a century, Eli Lilly and Co. has pushed for innovation in the pharmaceutical industry. But six years ago, the drugmaker had to admit it was less than innovative in its own workforce.
Eli Lilly on Thursday said in a government filing that it has received a subpoena from the U.S. Justice Department for documents related to the factory and is cooperating with the investigation.
Shares of Eli Lilly and Co. dropped as much as 5% Tuesday morning after the Indianapolis-based drugmaker lowered guidance for full-year earnings.
The Indianapolis-based company is asking U.S. regulators to revoke their emergency authorization for the use of bamlanivimab alone, in favor of its combination with another drug.
Stephen Fry, Eli Lilly and Co.’s senior vice president for human resources and diversity, told a legislative committee Tuesday that the company believed the bill aimed at reducing voter fraud wasn’t needed.
Sonya Elling filed suit Friday in federal court against the drugmaker, alleging that Leigh Ann Pusey, senior vice president for corporate affairs and communications, precluded her from engaging with members of Congress because she was “not a cute, young thing.”
The expert panel for the Food and Drug Administration voted 19-1 that the drug’s modest benefits don’t outweigh its considerable risks, even with proposed measures to restrict who gets the medicine.
Eli Lilly and Co. on Saturday morning presented highly anticipated details from a mid-stage study showing that its experimental drug slowed Alzheimer’s disease progression over about 18 months.
Eli Lilly and Co. told Reuters news agency that it is working closely with the FDA to address concerns about the factory in Branchburg, New Jersey, which makes Trulicity.
The Indianapolis-based drugmaker said it will begin shipping the additional doses immediately to the federal government, which controls distribution of the drugs.
